Form 4: MAIA Biotechnology Director Stan Smith Acquires Shares and Warrants

Director Stan Smith reports the acquisition of MAIA Biotechnology shares and warrants through a recent transaction.

Summary

• On April 25, 2024, Stan Smith, a director of MAIA Biotechnology, acquired 147,492 shares of common stock at $2.03 per share.
• The purchase was made pursuant to a Securities Purchase Agreement dated April 22, 2024, and the shares were issued under the Issuer's 2021 Equity Incentive Plan.
• Smith also acquired warrants to purchase 147,492 shares of common stock with an exercise price of $2.26.
• The warrants are exercisable beginning on October 25, 2024, and expire on October 25, 2029.
• Following the transaction, Smith beneficially owns 1,005,060 shares indirectly through The Stan V. Smith Trust Dated 1993, as well as 147,492 warrants indirectly through the same trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director purchasing shares suggests confidence, but it's a single transaction and doesn't provide a comprehensive view of the company's overall health.

Positives

• A director's purchase of shares can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in the biotechnology industry. Monitoring such transactions can provide insights into management's sentiment about the company's prospects.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates